Quarterly ResultAug 6, 2026, 04:34 PM
Profound Medical Q2 Revenue $2.5M; Net Loss Improves 39% to $9.5M
AI Summary
Profound Medical reported Q2 2026 revenue of $2.5 million, a 12% year-over-year increase, with a net loss of $9.5 million, a 39% improvement. The company noted that $3.1 million in TULSA product shipments were delayed to Q3, which would have boosted Q2 revenue to $5.6 million, representing 153% year-over-year growth. Profound reiterated its full-year 2026 revenue guidance of approximately $25.0 million and announced new employer health plans covering the TULSA Procedure, further expanding payer coverage.
Key Highlights
- Q2 2026 total revenue was $2.5 million, up 12% year-over-year.
- Adjusted Q2 revenue (excluding $3.1M shipment delay) would have been $5.6 million, up 153% YoY.
- Net loss improved 39% year-over-year to $9.5 million ($0.26 per share).
- Operating expenses declined 16% year-over-year to $13.0 million.
- Gross margin expanded to 78% in Q2 2026 from 73% in Q2 2025.
- Reiterated full-year 2026 revenue guidance of approximately $25.0 million.
- Received over $7.0 million in new purchase orders during Q2 2026.
- Cash and equivalents stood at approximately $38.3 million as of June 30, 2026.
Price Impact
More from PROF